FDA Creates Fecal Transplant Regulations

The FDA has announced that fecal microbiota for transplantation is a biological product and drug, which will require an investigational new drug application to be submitted before use, according to an Infectious Disease Special Addition report.  

Advertisement

FMT is currently used as a treatment for Clostridium difficile infection. The FDA’s regulatory actions are intended to protect patients from unnecessary risk.

Many have criticized the FDA for enacting strict regulations of a treatment that, as of yet, has shown little negative consequence.

More Articles on Gastroenterology:
3 Benefits of Outsourcing Colonoscopy Prep
UHC Recruits Dr. Adam Hansen, Gastroenterology Specialists
AbbVie, Galapagos Partner to Test Possible Chrohn’s Disease Drug

Advertisement

Next Up in GI & Endoscopy

  • Gastroenterologists are raising concerns about the CMS’ finalized payment policies, according to a joint statement from the American College of…

  • As gastroenterology evolves, leaders are reimagining how to deliver comprehensive, patient-centered care.  Dinesh Madhok, MD, CEO of Jacksonville, Fla.-based Borland…

Advertisement

Comments are closed.